Simon Farrell 4
4 · Trevi Therapeutics, Inc. · Filed Mar 8, 2023
Insider Transaction Report
Form 4
Simon Farrell
Chief Commercial Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2023-03-07−18,750→ 56,250 totalExercise: $0.51Exp: 2032-02-10→ Common Stock (18,750 underlying) - Exercise/Conversion
Common Stock
2023-03-07$0.51/sh+18,750$9,581→ 39,400 total
Footnotes (1)
- [F1]This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.